An observational study in Depression - Major Depressive Disorder and Anxiety, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Norwegian University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Depression with a site in Norway — 22 open to participants now, 31 under way, none of them phase 3. Depression · Norway.
Among the 109 studies in Depression with a site in Norway, this one is the 21st largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2024, is one of 28 observational ones, reaches primary completion later than 27 of the 30 other live ones, and was the 101st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →22 of the 109 studies in Depression with a site in Norway are open now. Recruiting first, the newest first:
Sorlandet Hospital HF · Sites in Norway
Ages 16–25
University of Bergen · Sites in Norway
Ages 18–40 · Healthy volunteers
University Hospital of North Norway · Sites in Norway
Ages 18–65
Solli Distriktspsykiatriske Senter · Sites in Norway
Ages 18–65
Oslo University Hospital · Sites in Norway
Ages 13–18
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 4 · Phase 4 2
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 170 across the 81 interventional studies, 575 across the 28 observational. Of the 68 that completed or were terminated, 3 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 109 have an industry lead sponsor. The 10 most frequent:
Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.
Norwegian University of Science and Technology has 8 studies filed under Depression — fewer than ten, so there is no comparison to draw.
7 of the studies in Depression with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05734547Norwegian Center for Violence and Traumatic Stress StudiesStepping Together for Children After Trauma, Norway | 2026-12-01 |
| NCT07864324University Hospital of North NorwayHigh-Intensity Interval Training and Mental Health in Psychiatric Inpatients | 2026-12-15 |
| NCT06777693NKS Olaviken Gerontopsychiatric HospitalThe Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Older Adults: a Feasibility Study | 2026-12-24 |
| NCT07000799University of OsloA Study of School Absenteeism and Student Well-being in Elementary Schools | 2026-12-31 |
| NCT06568419Solli Distriktspsykiatriske SentereBehandling - Health and Work for Patients in Specialist Mental Health Care | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 109 studies in Depression with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.
The study is a naturalistic study exploring cognitive functioning of patients with common mental disorders (CMD) treated with metacognitive therapy and work focused interventions, and changes over time.
Sick leave is common for patients with CMD, also after having completed treatment for CMD. Why patients remain on sick leave after having completed treatment is underexplored. Potential reasons may be that work and sick leave is not addressed during therapy, there could be issues related to the work place, also there may be characteristics related to the patients functioning that is underexplored. In the latter context, little knowledge regarding the relations between cognitive functioning, symptoms of CMD and work functioning. Previous studies have investigated neuropsychological functions in relation to work related stress and stress-related exhaustion, and found worse performance on cognitive tasks compared to healthy controls. Although stress-related exhaustion can be considered a phenomenon related to CMD, there are no studies the investigators are aware of that investigate neuropsychological predictors specifically related to CMD and work functioning. A review from 2022 specifically aimed to identify neuropsychological predictors of vocational rehabilitation outcomes in individuals with MDD specifically, and found no studies. This clearly demonstrates a knowledge gap that this project would fill. E.g., lower cognitive functioning after successful treatment of CMD is related to increased risk of additional sick leave. With this in mind, increasing our knowledge of these variables can help clinicians identify patients at risk for additional sick leave, even after successful treatment. A previous study at the same clinic has identified three subgroups in a sample of patients with CMD at risk of sick leave. The first group was never on sick leave. The second group returned to work after sick leave during or shortly after treatment. In the third group half of the patients remained on sick leave or disability. To better understand characteristics of such subgroups it is relevant to explore standard clinical information given in the patient's journal. This project is mainly, but not exclusively a PhD-project. The time schedule for the project will go beyond the time for the PhD, especially long-time follow-up.
The main aims of the project are the following:
To explore how descriptive variables, CMD symptoms, and cognitive functioning are associated with work functioning (sick leave or risk for sick leave) before treatment. And what is the interplay between symptoms, cognitive profiles and sick leave.
To explore whether cognitive functioning can predict outcomes of both symptoms of CMD and degree of sick leave, and if cognitive functioning changes through MCT and work focused interventions.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 200 is above the median of 175 across 1,261 observational studies indexed under Depression.
Browse Depression studies →Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients referred with depression and/or anxiety disorders at risk of sick leave.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients referred with depression and/or anxiety and at risk of sick leave
Patient Health Questionnaire-9 (PHQ-9)
Measure of depressive symptoms (PHQ-9) range 0-27 higher scores indicate higher degree of depressive symptoms
Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up
Generalized Anxiety Disorder (GAD-7)
Anxiety symptoms (GAD-7) range 0-21 higher scores indicating higher degree of anxiety symptoms
Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up
Changes in sick leave
Sick leave is collected from national register data measured in number of days of sick leave.
Time frame: Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up
Plan to share: No — Due to ethical considerations as this is a clinical study that includes patients with depression and/or anxiety at risk of sick leave, information will not be shared
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Aug 2029, 67 months after the start.
Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 67 months is above that.
Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →